Compare Dishman Pharma with ALEMBIC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ALEMBIC - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ALEMBIC 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ALEMBIC DISHMAN PHARMA/
ALEMBIC
 
P/E (TTM) x 25.1 77.6 32.3% View Chart
P/BV x 3.3 6.7 50.0% View Chart
Dividend Yield % 0.7 0.2 435.6%  

Financials

 DISHMAN PHARMA   ALEMBIC
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ALEMBIC
Mar-18
DISHMAN PHARMA/
ALEMBIC
5-Yr Chart
Click to enlarge
High Rs37472 520.0%   
Low Rs12934 380.2%   
Sales per share (Unadj.) Rs197.84.7 4,208.0%  
Earnings per share (Unadj.) Rs21.26.1 347.4%  
Cash flow per share (Unadj.) Rs34.76.2 556.0%  
Dividends per share (Unadj.) Rs2.000.20 1,000.0%  
Dividend yield (eoy) %0.80.4 210.4%  
Book value per share (Unadj.) Rs179.940.7 442.4%  
Shares outstanding (eoy) m80.69267.03 30.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.311.3 11.3%   
Avg P/E ratio x11.98.7 136.8%  
P/CF ratio (eoy) x7.28.5 85.5%  
Price / Book Value ratio x1.41.3 107.4%  
Dividend payout %9.43.3 287.8%   
Avg Mkt Cap Rs m20,30614,139 143.6%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,355207 2,581.9%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,9611,255 1,271.6%  
Other income Rs m265370 71.7%   
Total revenues Rs m16,2261,625 998.3%   
Gross profit Rs m4,103111 3,693.2%  
Depreciation Rs m1,09138 2,885.2%   
Interest Rs m9442 55,552.9%   
Profit before tax Rs m2,334442 528.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m11,212 0.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62424 2,603.8%   
Profit after tax Rs m1,7111,630 105.0%  
Gross profit margin %25.78.9 290.5%  
Effective tax rate %26.75.4 492.9%   
Net profit margin %10.7129.8 8.3%  
BALANCE SHEET DATA
Current assets Rs m11,0181,867 590.1%   
Current liabilities Rs m9,517591 1,609.8%   
Net working cap to sales %9.4101.6 9.3%  
Current ratio x1.23.2 36.7%  
Inventory Days Days11094 117.2%  
Debtors Days Days3574 47.4%  
Net fixed assets Rs m16,3041,791 910.4%   
Share capital Rs m161534 30.2%   
"Free" reserves Rs m12,90710,324 125.0%   
Net worth Rs m14,51610,858 133.7%   
Long term debt Rs m4,18941 10,168.4%   
Total assets Rs m29,80511,591 257.2%  
Interest coverage x3.5260.9 1.3%   
Debt to equity ratio x0.30 7,606.1%  
Sales to assets ratio x0.50.1 494.5%   
Return on assets %8.914.1 63.3%  
Return on equity %11.815.0 78.5%  
Return on capital %17.515.2 115.4%  
Exports to sales %24.81.5 1,603.8%   
Imports to sales %3.721.0 17.8%   
Exports (fob) Rs m3,95619 20,392.8%   
Imports (cif) Rs m596263 226.4%   
Fx inflow Rs m4,95219 25,523.2%   
Fx outflow Rs m697264 264.1%   
Net fx Rs m4,255-244 -1,740.7%   
CASH FLOW
From Operations Rs m2,786236 1,181.7%  
From Investments Rs m-1,529-224 682.5%  
From Financial Activity Rs m-941-27 3,538.0%  
Net Cashflow Rs m316-15 -2,137.8%  

Share Holding

Indian Promoters % 61.4 64.0 95.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 0.2 1,850.0%  
FIIs % 12.7 9.7 130.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 26.1 84.7%  
Shareholders   46,261 54,701 84.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   WYETH  PIRAMAL ENTERPRISES  JUBILANT PHARMOVA   NEULAND LABS  PFIZER  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - STRIDES PHARMA SCIENCE COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS